How many insider trades does FilingIQ track for TCRX?

FilingIQ tracks 62 Form 4 insider transactions for TCRX (TScan Therapeutics, Inc.), covering filings from Jul 20, 2021 onwards. 7 of those were filed in the last 90 days.

Are TCRX insiders net buyers or net sellers?

Across the full Form 4 history for TCRX, 39 transactions (63%) were open-market purchases and 4 (6%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does TCRX insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is TCRX in?

TScan Therapeutics, Inc. (TCRX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $59.75M.

TCRX insider trading

NasdaqGM Healthcare

TScan Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

63% / 6%

Market cap

$59.75M

About TScan Therapeutics, Inc.

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Company website: www.tscan.com

TCRX insider activity at a glance

FilingIQ has scored 62 insider transactions for TCRX since Jul 20, 2021. The most recent filing in our index is dated May 20, 2026.

Across the full history, 39 open-market purchases and 4 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on TCRX insider trades is 51.7/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live TCRX trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,265

UNITED THERAPEUTICS Corp

APLS 277

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

GH 195

Guardant Health, Inc.

ADPT 184

Adaptive Biotechnologies Corp

BMY 182

BRISTOL MYERS SQUIBB CO

VTRS 165

Viatris Inc

ALNY 153

ALNYLAM PHARMACEUTICALS, INC.

Frequently asked

How many insider trades does FilingIQ track for TCRX?: FilingIQ tracks 62 Form 4 insider transactions for TCRX (TScan Therapeutics, Inc.), covering filings from Jul 20, 2021 onwards. 7 of those were filed in the last 90 days.
Are TCRX insiders net buyers or net sellers?: Across the full Form 4 history for TCRX, 39 transactions (63%) were open-market purchases and 4 (6%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does TCRX insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is TCRX in?: TScan Therapeutics, Inc. (TCRX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $59.75M.

Methodology & sources

Every TCRX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.